Business Wire

Maropost bolsters product leadership team to accelerate innovation and growth

21.5.2024 20:15:00 EEST | Business Wire | Press release

Share

Maropost, the commerce software suite built for fast-growing commerce brands, announces two significant appointments to its senior leadership team: Tim Schulz joins as VP of Product, Commerce Cloud, and Alessandra "Alex" Jacques steps in as VP of Product, Marketing Cloud.

"I founded Maropost to disrupt a crowded market, and with Tim and Alex on board, we are aggressively pursuing that vision," said Maropost Chairman and CEO Ross Andrew Paquette. "We're building a single platform that puts fast-growing retailers in control of their customer journeys, from hyper-personalized marketing to in-store and online purchases through exceptional service.

"Brands will use Maropost to create and manage product catalogs, centrally design and deploy promotions across all their channels, build engaging storefronts, and deliver personalized shopping experiences from one data set, in one nerve center."

Paquette is confident Maropost will achieve this mission. "We're not just another player in the market; we're here to redefine it. Watch closely: We're about to show what's possible when ingenuity meets determination."

About the New Appointees

Alex Jacques brings deep product management expertise from her roles at Terminus and Cheetah Digital. A certified CSM and CSPO, she excels at leading highly functional scrum teams, managing multiple platforms, and driving customer experience strategies. Her marketing technology prowess will shape the future of Marketing Cloud.

Tim Schulz is a seasoned product and technology leader with a track record of delivering outstanding results. As Head of Product at Magento and VTEX, he built products that enabled mid-market and enterprise retailers to scale their businesses globally and respond to shifts in the industry. At BigCommerce, he led Product & Engineering and grew revenue to over $100 million ARR in 24 months while launching strategic partnerships with top tech companies, including Facebook, Twitter, Google, and Alibaba.

Tim was also a top 5% performer at Google, where he led global platform partnerships for Google Shopping and drove 40 full-cycle enterprise deals across product lines. At Maropost, Tim will direct the development of future commerce products.

"We're thrilled to welcome Alex and Tim to the Maropost team," said Sean Brady, COO and President of Maropost. "Their extensive product expertise, proven leadership, and passion for delivering exceptional customer experiences will help us realize our vision of a unified platform that helps them grow, scale, and drive real value from their marketing, commerce, and service efforts."

About Maropost

Only Maropost unites the commerce tools and insights growing brands need to engage customers and scale their business. Built on unified customer data and an enterprise-grade infrastructure, Maropost offers a complete, connected suite of marketing, merchandising and search, customer service, ecommerce, and retail solutions.

Since its founding in 2011, Maropost has made multiple appearances on Deloitte's Technology Fast 500 list and G2's leaderboard. A global company, Maropost proudly serves 5,000+ leading commerce brands across North America, Australia, and Europe, including Victoria Beckham, Sandro Paris, Untuckit, Scott Sports, James Perse, and Fujifilm.

Learn more at www.maropost.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Rob Wade
(888) 438-3152
press@maropost.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye